Neoadjuvant endocrine therapy for breast cancer

Jane S Chawla; Cynthia X Ma; Matthew J Ellis

doi:10.1016/j.soc.2010.04.004

Neoadjuvant endocrine therapy for breast cancer

Surg Oncol Clin N Am. 2010 Jul;19(3):627-38. doi: 10.1016/j.soc.2010.04.004.

Authors

Jane S Chawla¹, Cynthia X Ma, Matthew J Ellis

Affiliation

¹ Division of Oncology, Department of Medicine, Washington University, 660 South Euclid Avenue, St Louis, MO 63110, USA.

PMID: 20620931
DOI: 10.1016/j.soc.2010.04.004

Abstract

Neoadjuvant endocrine therapy improves surgical outcomes for postmenopausal women with bulky hormone receptor-positive breast cancer. Recent studies indicate that this approach may also be used in the management of smaller tumors with the hope of predicting outcomes from adjuvant endocrine manipulation. Neoadjuvant endocrine therapy provides a unique opportunity to identify molecular predictors of endocrine responsiveness and agents that can be used in combination with endocrine therapy to improve tumor response and overcome endocrine resistance.

Publication types

Review

MeSH terms

Antineoplastic Agents, Hormonal / therapeutic use*
Breast Neoplasms / drug therapy*
Chemotherapy, Adjuvant
Endocrine System / drug effects*
Female
Humans
Neoadjuvant Therapy*

Substances

Antineoplastic Agents, Hormonal